MEDIA

November 27, 2024, Hsinchu
GBC Corporation (referred to as “GBC,” stock code: 4117), a leader in precision medicine, has been honored with the 33rd “2024 Taiwan Excellence Award” for its fully automated CellBio™ Circulating Tumor Cell (CTC) Detection System. Recognized for its high precision, efficiency, and non-invasive approach, the product is revolutionizing early cancer detection and monitoring, making a profound impact on global cancer screening practices. This accolade underscores GBC’s outstanding R&D and manufacturing capabilities in the field of precision medicine.

The CellBio™ Circulating Tumor Cell (CTC) Detection System excels with high capture rates and detection precision for cancer cells. It can process up to 10 samples simultaneously, significantly reducing detection time and minimizing manual intervention. By extracting only 7.5 milliliters of blood, the system effectively isolates and captures rare cancer cells in a non-invasive manner, accurately identifying the number of cancer cells in the blood and monitoring their dynamic changes. With a cancer cell capture rate exceeding 90%, this innovation provides a more reliable solution for early cancer screening. It also assists doctors in health monitoring during treatment, particularly in tracking the effectiveness of treatments and the risk of recurrence for known cancer patients, offering accurate and intuitive data for enhanced medical care.

In its commitment to expanding Taiwan’s cancer screening market, GBC has signed an exclusive agreement with Fubon Life Insurance to offer the “Next-Generation myCTC Blood Circulating Tumor Cell Detection” service to new policyholders. As of October 2024, over 25,000 cases have been completed under this collaboration. GBC continues to deepen its partnership with Fubon and plans to introduce new products while actively seeking collaboration opportunities with hospitals and clinics across Taiwan. These efforts are expected to positively contribute to the company’s future operations.

Looking ahead, GBC is optimistic about the growing market demand for precision medical diagnostics and liquid biopsies. The company is focused on advancing its five core business areas: precision diagnostics, liquid biopsy, CDMO (Contract Development and Manufacturing Organization), diagnostic services, and P113 antimicrobial peptide pharmaceuticals. Leveraging its comprehensive supply chain that spans R&D, manufacturing, sales, and diagnostic services, GBC is steadfast in its mission to “start with diagnostics and collaborate with healthcare partners to protect public health.” The company continues to invest in molecular diagnostics and cancer-related liquid biopsy technologies, aiming to expand its service portfolio and align with the global trend toward precision health.